Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Melzer

Showing results (11-20 of 30) with videos related to

Pageof 3
Sort By:
The British Journal of Dermatology|June 6, 2017
Secukinumab is superior to fumaric acid esters in treating patients with moderate-to-severe plaque psoriasis who are naive to systemic treatments: results from the randomized controlled PRIME trialM Sticherling, U Mrowietz, M Augustin, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|September 30, 2017
Secukinumab treatment of moderate to severe plaque psoriasis in routine clinical care: real-life data of prior and concomitant use of psoriasis treatments from the PROSPECT studyA Körber, D Thaçi, R von Kiedrowski, et al.
Thrombosis Research|June 11, 2011
Certoparin versus UFH to prevent venous thromboembolic events in the very elderly patient: an analysis of the CERTIFY studyS M Schellong, H-E Gerlach, U Tebbe, et al.
Thrombosis and Haemostasis|April 21, 2011
CERTIFY: prophylaxis of venous thromboembolism in patients with severe renal insufficiencyR Bauersachs, S M Schellong, S Haas, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|September 22, 2019
Secukinumab is effective in treatment of moderate-to-severe plaque psoriasis: real-life effectiveness and safety from the PROSPECT studyD Thaçi, A Körber, R von Kiedrowski, et al.
The British Journal of Dermatology|April 12, 2019
Continued treatment with secukinumab is associated with high retention or regain of responseM Augustin, D Thaci, K Eyerich, et al.
European Journal of Neurology|October 28, 2016
Anti-contactin-associated protein-2 encephalitis: relevance of antibody titres, presentation and outcomeC G Bien, Z Mirzadjanova, C Baumgartner, et al.
Physical Review Letters|January 5, 2019
Breakdown of the Spectator Concept in Low-Electron-Energy Resonant Decay ProcessesA Mhamdi, J Rist, D Aslitürk, et al.
Journal of Neuroinflammation|June 25, 2017
Identification of the flotillin-1/2 heterocomplex as a target of autoantibodies in bona fide multiple sclerosisS Hahn, G Trendelenburg, M Scharf, et al.
Physical Review Letters|November 26, 2019
Photon-Momentum-Induced Molecular Dynamics in Photoionization of N_{2} at hν=40  keVM Kircher, J Rist, F Trinter, et al.
Pageof 3

Showing results (11-20 of 30) with videos related to

Sort By:
Pageof 3
The British Journal of Dermatology|June 6, 2017
Secukinumab is superior to fumaric acid esters in treating patients with moderate-to-severe plaque psoriasis who are naive to systemic treatments: results from the randomized controlled PRIME trialM Sticherling, U Mrowietz, M Augustin, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|September 30, 2017
Secukinumab treatment of moderate to severe plaque psoriasis in routine clinical care: real-life data of prior and concomitant use of psoriasis treatments from the PROSPECT studyA Körber, D Thaçi, R von Kiedrowski, et al.
Thrombosis Research|June 11, 2011
Certoparin versus UFH to prevent venous thromboembolic events in the very elderly patient: an analysis of the CERTIFY studyS M Schellong, H-E Gerlach, U Tebbe, et al.
Thrombosis and Haemostasis|April 21, 2011
CERTIFY: prophylaxis of venous thromboembolism in patients with severe renal insufficiencyR Bauersachs, S M Schellong, S Haas, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|September 22, 2019
Secukinumab is effective in treatment of moderate-to-severe plaque psoriasis: real-life effectiveness and safety from the PROSPECT studyD Thaçi, A Körber, R von Kiedrowski, et al.
The British Journal of Dermatology|April 12, 2019
Continued treatment with secukinumab is associated with high retention or regain of responseM Augustin, D Thaci, K Eyerich, et al.
European Journal of Neurology|October 28, 2016
Anti-contactin-associated protein-2 encephalitis: relevance of antibody titres, presentation and outcomeC G Bien, Z Mirzadjanova, C Baumgartner, et al.
Physical Review Letters|January 5, 2019
Breakdown of the Spectator Concept in Low-Electron-Energy Resonant Decay ProcessesA Mhamdi, J Rist, D Aslitürk, et al.
Journal of Neuroinflammation|June 25, 2017
Identification of the flotillin-1/2 heterocomplex as a target of autoantibodies in bona fide multiple sclerosisS Hahn, G Trendelenburg, M Scharf, et al.
Physical Review Letters|November 26, 2019
Photon-Momentum-Induced Molecular Dynamics in Photoionization of N_{2} at hν=40  keVM Kircher, J Rist, F Trinter, et al.
Pageof 3